Michigan SB 223, legislation that would mandate additional reporting on the use of animals in research and establish formal processes for...
Read PostState Advocacy
Michigan Matters: Advocacy at the State Level
Discover the latest updates and initiatives shaping Michigan's bio-industry through state-level advocacy. From policy developments to impactful actions, this category focuses on driving progress and innovation within our state.
The Michigan Senate’s proposal to eliminate the $15.7 million Innovation and Entrepreneurship budget line threatens to dismantle the very...
Read PostMichBio was proud to once again participate in the annual Mackinac Policy Conference—an influential gathering of business, legislative, and...
Read PostIn the aftermath of the Mackinac Policy Conference, it was a privilege to meet directly with Governor Whitmer at the State Capitol this week and...
Read PostSurgical smoke, the byproduct of heat-producing devices such as electrocautery units and lasers, poses a significant yet often overlooked...
Read PostRecent changes to Michigan's consumer protection laws have sparked debate, and a coalition of Michigan industry groups have joined to oppose the...
Read PostMichigan’s legislature is considering two bills, SB 94 and SB 95 related to the federal 340B Drug Pricing Program and both bills are...
Read PostTwo bills, HB 4332 and HB 4333 were recently re-introduced that would prohibit pathogen gain-of-function (GoF) research. Given that the...
Read PostLegislation Aims to Ban Animal Research at Public Universities Legislation referred to as “Queenie’s Law,” was reintroduced in...
Read PostMichigan Senate Passes Controversial 340B Program Bills The Michigan Senate overwhelmingly passed bills, SB 94 and SB 95, that “prohibits...
Read PostStay updated on Michigan's Earned Sick Time Act changes, including new employer requirements and employee rights. Learn how these updates impact...
Read PostStay updated on Michigan's 340B contract pharmacy access legislation. Explore its implications for healthcare costs and transparency in drug pricing.
Read Post